interferon alfa-2b 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
5205 98530-12-2

Description:

MoleculeDescription

Synonyms:

  • interferon alfa-2b
  • intron A
  • interferon alfa-2b recombinant
Interferon alfa-2b is an alpha interferon and is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Once bound to the cell membrane, interferons initiate a complex sequence of intracellular events. In vitro studies demonstrated that these include the induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells. Interferon alfa via inhalation is included in national guidelines from China as a possible option for treatment of COVID-19.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2 MU P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
June 4, 1986 FDA SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product use in unapproved indication 97.52 31.71 62 1352 336174 90290859
Influenza like illness 63.53 31.71 29 1385 80582 90546451
Product dose omission issue 54.15 31.71 41 1373 291646 90335387
Off label use 52.36 31.71 74 1340 1102178 89524855
Hepatitis cholestatic 42.16 31.71 12 1402 8549 90618484
Fatigue 39.92 31.71 67 1347 1153956 89473077
Bladder cancer recurrent 38.57 31.71 6 1408 223 90626810

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Influenza like illness 115.15 29.97 45 1743 31795 42587752
Product use in unapproved indication 111.37 29.97 78 1710 184378 42435169
Off label use 52.11 29.97 94 1694 638241 41981306
Fatigue 44.42 29.97 71 1717 435570 42183977
Product use issue 40.38 29.97 30 1758 76721 42542826
Sticky platelet syndrome 37.16 29.97 5 1783 21 42619526
Varicophlebitis 36.97 29.97 5 1783 22 42619525
Adverse event 35.25 29.97 18 1770 23622 42595925
Bladder cancer recurrent 35.01 29.97 7 1781 408 42619139
Restrictive cardiomyopathy 30.88 29.97 7 1781 743 42618804

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product use in unapproved indication 151.35 28.78 109 2677 447268 110139245
Off label use 111.44 28.78 160 2626 1500025 109086488
Influenza like illness 105.08 28.78 49 2737 88363 110498150
Bladder cancer recurrent 75.48 28.78 13 2773 560 110585953
Fatigue 52.26 28.78 102 2684 1215856 109370657
Sticky platelet syndrome 39.90 28.78 5 2781 20 110586493
Retinal exudates 36.13 28.78 8 2778 1276 110585237
Varicophlebitis 35.36 28.78 5 2781 57 110586456
Hypophosphataemia 35.09 28.78 17 2769 33165 110553348
Restrictive cardiomyopathy 32.01 28.78 7 2779 1054 110585459
Rectal neoplasm 31.55 28.78 5 2781 128 110586385
Cutaneous sarcoidosis 30.26 28.78 6 2780 561 110585952
Ulcerative keratitis 29.99 28.78 9 2777 4757 110581756
Vogt-Koyanagi-Harada disease 29.77 28.78 6 2780 610 110585903

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L03AB05 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Interferons
FDA CS M0025711 Interferon-alpha
FDA EPC N0000175521 Interferon alpha
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000998 Antiviral Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:62868 hepatoprotective agent
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:64951 anti-HBV agent

Related Drugs by ATC class:

L03AB Interferons 6 drugs
interferon beta-1ainterferon beta-1bpeginterferon alfa-2apeginterferon alfa-2bpeginterferon beta-1aropeginterferon alfa-2b

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Follicular lymphoma indication 55150002
Chronic type B viral hepatitis indication 61977001
Hairy cell leukemia indication 118613001
Chronic hepatitis C indication 128302006
Condyloma acuminatum indication 240542006 DOID:11168
Malignant melanoma indication 372244006
Kaposi's sarcoma associated with AIDS indication 420524008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
43K1W2T1M6 UNII
4018794 VANDF
4021035 VANDF
4022538 VANDF
C0021735 UMLSCUI
CHEBI:749428 CHEBI
CHEMBL1201558 ChEMBL_ID
CHEMBL2107842 ChEMBL_ID
71306834 PUBCHEM_CID
DB00105 DRUGBANK_ID
D02745 KEGG_DRUG
D000077190 MESH_DESCRIPTOR_UI
DB15131 DRUGBANK_ID
108797002 SNOMEDCT_US
386915008 SNOMEDCT_US
d01369 MMSL
2420 MMSL
2428 MMSL
4892 MMSL
003424 NDDF
545290 RXNORM

Pharmaceutical products:

None